Mineralys Therapeutics MLYS 深 沪
已收盘 10-16 16:00:00 美东时间
20.30
-1.340
-6.19%
华盛通- 最 高21.60
- 今 开21.60
- 成交量 118.12万股
- 最 低 20.12
- 昨 收 21.64
- 总市值 17.95亿
- 52周最高 47.65
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 20.12
- 委 比 -3.09%
- 总股本 8840.69万
- 历史最高 47.65
- 量 比 0.79
- 振 幅 6.84%
- 历史最低 5.85
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mineralys Therapeutics收跌6.19%，成交额2420.66万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
今天 05:31
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-12 21:20
Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldost...
10-09 21:04
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics announced positive results from its Phase 3 Launch-HTN trial, showing that 46% of participants with difficult-to-treat hypertension achieved a systolic blood pressure below 130 mmHg after 12 weeks of treatment with lorundrostat 50 mg. Additionally, 70% of participants saw a 10 mmHg reduction in systolic blood pressure. In the Phase 2 Explore-OSA trial, lorundrostat demonstrated clinically meaningful reductions in morning sy...
10-09 13:00
Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldo...
10-02 04:06
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics announced the presentation of five abstracts at the American Heart Association Hypertension Scientific Sessions 2026, highlighting the efficacy and safety of its investigational drug, Lorundrostat, in treating hypertension and related conditions such as obstructive sleep apnea and chronic kidney disease. The presentations include one oral and four poster sessions, showcasing data from clinical trials like Launch-HTN and Exp...
10-01 20:05
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics授予两位新员工总计46,430股股票期权和34,823股限制性股票单位，归属期为四年。公司专注于开发治疗高血压及相关并发症的药物，其主要候选药物为lorundrostat。Mineralys总部位于宾夕法尼亚州，联系方式为investorrelations@mineralystx.com。
09-29 20:05
Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated...
09-24 04:07
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Mineralys Therapeutics announced that long-term efficacy and safety data from its ongoing Transform-HTN trial of lorundrostat, an aldosterone synthase inhibitor, will be presented at the American Heart Association Scientific Sessions 2026. The presentation, titled "Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat in Uncontrolled Hypertension," will be delivered by Dr. Manish Saxena on November 8, 2026, in Chicago. The Transform-HTN tr...
09-23 20:05
